美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Aegerion制药

1.97

0.0000

成交量：- -

成交额：- -

市值：5,820.38万

市盈率：-0.33

高：1.97

开：1.97

低：1.97

收：1.97

52周最高：10.85

52周最低：1.23

股本：2,954.51万

流通股本：1,428.97万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-5.9700

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Aegerion制药

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.aegerion.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Aegerion Pharmaceuticals, Inc.是一家生物制药公司,致力于为那些衰弱的、患有致命罕见疾病的人开发新奇的，并且能够挽救生命的治疗方法并将其用于商业用途。公司的第一个产品JUXTAPID，在2012年12月21日得到了美国食品和药物管理局的营销批准，并作为对低脂肪饮食和其他降脂治疗的补充，包括低密度脂蛋白(LDL)血清法，如果可用，可降低纯合子家族性高胆固醇血症患者(HoFH)的低密度脂蛋白胆固醇(低密度)、总胆固醇(TC)、载脂蛋白B(B朊)和非高密度脂蛋白胆固醇(non-HDL-C)。2013年1月底，该公司在美国推出了JUXTAPID。在2012年的第一季度,它向欧洲药品局(EMA)提交了营销授权申请(MAA)请求批准上市，作为低脂肪饮食和其他降脂治疗的辅助，在用或是不用血清法的条件下减少患有血症的成年人体内的低密度脂蛋白、TC、载脂蛋白B和甘油三酯(TG)。公司于2005年2月在特拉华州法律下成立。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/AEGR/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AEGR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AEGR\",,,,,undefined,":{"symbol":"AEGR","market":"US","secType":"STK","nameCN":"Aegerion制药","latestPrice":1.97,"timestamp":1480539600000,"preClose":1.97,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":14289727,"shares":29545088,"eps":-5.97,"marketStatus":"交易中","change":0,"latestTime":"03-25 10:38:51 EDT","open":1.97,"high":1.97,"low":1.97,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.97,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1774468800000},"marketStatusCode":2,"adr":0,"listingDate":1287720000000,"exchange":"NASDAQ","adjPreClose":1.97,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AEGR\",,,,,undefined,":{"symbol":"AEGR","floatShares":14289727,"roa":"--","roe":"--","lyrEps":0,"shares":29545088,"dividePrice":0,"high":1.97,"amplitude":0,"preClose":1.97,"low":1.97,"week52Low":1.23,"pbRate":"--","week52High":10.85,"institutionHeld":0,"latestPrice":1.97,"eps":-5.97,"divideRate":0,"volume":0,"delay":0,"ttmEps":-5.97,"open":1.97,"prevYearClose":1.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AEGR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-11-03","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-0.67,"name":null,"time":"","type":"earning","dateTimestamp":1478145600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2016-08-09","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-0.25,"name":null,"time":"","type":"earning","dateTimestamp":1470715200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2016-05-16","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-1.85,"name":null,"time":"盘后","type":"earning","dateTimestamp":1463371200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2016-02-25","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-0.97,"name":null,"time":"盘后","type":"earning","dateTimestamp":1456376400000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2015-11-09","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-0.51,"name":null,"time":"盘后","type":"earning","dateTimestamp":1447045200000,"reportTimeType":"post","actualEps":0.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AEGR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AEGR\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.aegerion.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":-0.0526},{"period":"3month","weight":-0.0539},{"period":"6month","weight":-0.0074},{"period":"1year","weight":0.1378},{"period":"ytd","weight":-0.0421}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aegerion Pharmaceuticals, Inc.是一家生物制药公司,致力于为那些衰弱的、患有致命罕见疾病的人开发新奇的，并且能够挽救生命的治疗方法并将其用于商业用途。公司的第一个产品JUXTAPID，在2012年12月21日得到了美国食品和药物管理局的营销批准，并作为对低脂肪饮食和其他降脂治疗的补充，包括低密度脂蛋白(LDL)血清法，如果可用，可降低纯合子家族性高胆固醇血症患者(HoFH)的低密度脂蛋白胆固醇(低密度)、总胆固醇(TC)、载脂蛋白B(B朊)和非高密度脂蛋白胆固醇(non-HDL-C)。2013年1月底，该公司在美国推出了JUXTAPID。在2012年的第一季度,它向欧洲药品局(EMA)提交了营销授权申请(MAA)请求批准上市，作为低脂肪饮食和其他降脂治疗的辅助，在用或是不用血清法的条件下减少患有血症的成年人体内的低密度脂蛋白、TC、载脂蛋白B和甘油三酯(TG)。公司于2005年2月在特拉华州法律下成立。","exchange":"NASDAQ","name":"Aegerion制药","nameEN":"Aegerion Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"AEGR\",market:\"US\",,,undefined,":null}}